Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive data from the primary analysis of the phase III HAVEN 1 study in adults and adolescents and interim analysis of the phase III HAVEN 2 study in children evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) for the treatment of haemophilia A with inhibitors to factor VIII. Data from both studies will be presented on 10 July at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting in Berlin, Germany.


Share this story, choose your platform!